| Dr Susan E Nelson, MD | |
|
15 S Mchenry Rd, Buffalo Grove, IL 60089-6705 | |
| (847) 618-0351 | |
| (847) 618-0766 |
| Full Name | Dr Susan E Nelson |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 38 Years |
| Location | 15 S Mchenry Rd, Buffalo Grove, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144208612 | NPI | - | NPPES |
| 36076434 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 036076434 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwest Community Hospital 1 | Arlington heights, IL | Hospital |
| Advocate Lutheran General Hospital | Park ridge, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Community Health Services Inc | 3375737331 | 275 |
News Archive
By injecting multiwalled carbon nanotubes (MWCNTs) into tumors and heating them with a quick, 30-second zap of a laser, a multi-institutional team of researchers from the Wake Forest University School of Medicine (WFUSOM), Wake Forest University Center for Nanotechnology and Molecular Materials, Rice University, and Virginia Polytechnic Institute and State University has developed a new type of therapy that effectively kills kidney tumors in nearly 80% of treated mice. Researchers say that the findings, which were published in the Proceedings of the National Academy of Sciences of the United States of America, suggest a potential future cancer treatment for humans.
Even in an economy that's proved devastating to charitable giving and government grants, the Baylor Institute of Immunology Research (BIIR), a component of Baylor Research Institute (BRI), has managed to buck the trend: BIIR received grants totaling nearly $35 million in 2009.
As COVID-19 quickly spread worldwide this spring, shortages of supplies, including the nasopharyngeal (nasal) swabs used to collect viral samples, limited diagnostic testing.
Pearl Therapeutics Inc., a privately held company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), today announced a $69 million Series C financing. The financing round was led by Vatera Healthcare Partners and included existing investors, Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.
› Verified 1 days ago
| Entity Name | Northshore University Healthsystem Faculty Practice Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497701882 PECOS PAC ID: 2163334699 Enrollment ID: O20040524000118 |
News Archive
By injecting multiwalled carbon nanotubes (MWCNTs) into tumors and heating them with a quick, 30-second zap of a laser, a multi-institutional team of researchers from the Wake Forest University School of Medicine (WFUSOM), Wake Forest University Center for Nanotechnology and Molecular Materials, Rice University, and Virginia Polytechnic Institute and State University has developed a new type of therapy that effectively kills kidney tumors in nearly 80% of treated mice. Researchers say that the findings, which were published in the Proceedings of the National Academy of Sciences of the United States of America, suggest a potential future cancer treatment for humans.
Even in an economy that's proved devastating to charitable giving and government grants, the Baylor Institute of Immunology Research (BIIR), a component of Baylor Research Institute (BRI), has managed to buck the trend: BIIR received grants totaling nearly $35 million in 2009.
As COVID-19 quickly spread worldwide this spring, shortages of supplies, including the nasopharyngeal (nasal) swabs used to collect viral samples, limited diagnostic testing.
Pearl Therapeutics Inc., a privately held company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), today announced a $69 million Series C financing. The financing round was led by Vatera Healthcare Partners and included existing investors, Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.
› Verified 1 days ago
| Entity Name | Northwest Community Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134433154 PECOS PAC ID: 3375737331 Enrollment ID: O20101103000837 |
News Archive
By injecting multiwalled carbon nanotubes (MWCNTs) into tumors and heating them with a quick, 30-second zap of a laser, a multi-institutional team of researchers from the Wake Forest University School of Medicine (WFUSOM), Wake Forest University Center for Nanotechnology and Molecular Materials, Rice University, and Virginia Polytechnic Institute and State University has developed a new type of therapy that effectively kills kidney tumors in nearly 80% of treated mice. Researchers say that the findings, which were published in the Proceedings of the National Academy of Sciences of the United States of America, suggest a potential future cancer treatment for humans.
Even in an economy that's proved devastating to charitable giving and government grants, the Baylor Institute of Immunology Research (BIIR), a component of Baylor Research Institute (BRI), has managed to buck the trend: BIIR received grants totaling nearly $35 million in 2009.
As COVID-19 quickly spread worldwide this spring, shortages of supplies, including the nasopharyngeal (nasal) swabs used to collect viral samples, limited diagnostic testing.
Pearl Therapeutics Inc., a privately held company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), today announced a $69 million Series C financing. The financing round was led by Vatera Healthcare Partners and included existing investors, Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Susan E Nelson, MD 15 S Mchenry Rd, Buffalo Grove, IL 60089-6705 Ph: (847) 618-0351 | Dr Susan E Nelson, MD 15 S Mchenry Rd, Buffalo Grove, IL 60089-6705 Ph: (847) 618-0351 |
News Archive
By injecting multiwalled carbon nanotubes (MWCNTs) into tumors and heating them with a quick, 30-second zap of a laser, a multi-institutional team of researchers from the Wake Forest University School of Medicine (WFUSOM), Wake Forest University Center for Nanotechnology and Molecular Materials, Rice University, and Virginia Polytechnic Institute and State University has developed a new type of therapy that effectively kills kidney tumors in nearly 80% of treated mice. Researchers say that the findings, which were published in the Proceedings of the National Academy of Sciences of the United States of America, suggest a potential future cancer treatment for humans.
Even in an economy that's proved devastating to charitable giving and government grants, the Baylor Institute of Immunology Research (BIIR), a component of Baylor Research Institute (BRI), has managed to buck the trend: BIIR received grants totaling nearly $35 million in 2009.
As COVID-19 quickly spread worldwide this spring, shortages of supplies, including the nasopharyngeal (nasal) swabs used to collect viral samples, limited diagnostic testing.
Pearl Therapeutics Inc., a privately held company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), today announced a $69 million Series C financing. The financing round was led by Vatera Healthcare Partners and included existing investors, Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.
› Verified 1 days ago
Mr. Mark J Charman, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 W Lake Cook Rd, Buffalo Grove, IL 60089 Phone: 847-632-1880 Fax: 847-520-6095 | |
Olga Zarkh, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 135 N Arlington Heights Rd Ste 160, Buffalo Grove, IL 60089 Phone: 847-818-7700 Fax: 847-818-1718 | |
Dr. Gregory O'neal Clark, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 355 W Dundee Rd Ste 110, Buffalo Grove, IL 60089 Phone: 847-541-4878 Fax: 847-520-0500 | |
Dr. Sarah Cathleen Peterson, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 15 S Mchenry Rd, Buffalo Grove, IL 60089 Phone: 847-618-0326 Fax: 847-618-0762 | |
Dr. Chuck Richard Vrasich, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 15 S Mchenry Rd, Buffalo Grove, IL 60089 Phone: 847-618-0351 Fax: 847-618-0766 | |
Dr. Irina Goldvekht, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 15 S Mchenry Rd, Buffalo Grove, IL 60089 Phone: 847-618-0351 Fax: 847-618-0766 |